{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:45:13Z","timestamp":1792665913158,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Urokinase is often regarded as an older thrombolytic displaced by fibrin-selective agents in reperfusion medicine. Yet its decline has been uneven. This mini-review reframes its contemporary role through three determinants: route, compartment, and access. The systemic role of native urokinase has receded, particularly in stroke. Adjunctive thrombolysis after endovascular reperfusion remains unsettled: POST-UK and POST-TNK were neutral, whereas PEARL and ANGEL-TNK reported higher 90-day excellent-outcome rates. Trial differences preclude a uniform conclusion or generalization to primary intra-arterial thrombolysis and local fibrinolysis. Native urokinase retains a niche when delivered directly into clot-containing compartments or established catheters, including intracranial blood collections, chronic subdural hematoma, selected venous thromboembolism, loculated pleural disease, and catheter-related thrombotic dysfunction. In these settings, it functions as a low-cost, familiar, locally delivered fibrinolytic that facilitates clot clearance or drainage. Supporting evidence remains heterogeneous and often derives from retrospective cohorts, small studies, and variable protocols. Recombinant human prourokinase should be distinguished pharmacologically and clinically from native urokinase. As a zymogen precursor preferentially activated at the fibrin-rich thrombus surface, it represents a renewed systemic reperfusion pathway. Following the historical proof of concept provided by PROACT II, PROST and PROST-2 showed intravenous recombinant human prourokinase to be non-inferior to alteplase for excellent 90-day functional outcomes; PROST-2 additionally reported lower rates of symptomatic intracranial hemorrhage and major bleeding. External generalizability and direct comparison with tenecteplase remain unresolved. The contemporary urokinase pathway therefore reflects a dual evolution: native urokinase retains focused local and access-driven roles, whereas recombinant prourokinase has re-entered systemic reperfusion therapy.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1904249","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:13:27Z","timestamp":1790237607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Urokinase redux: route, compartment, access, and pharmacological evolution from native urokinase to recombinant prourokinase"],"prefix":"10.3389","volume":"13","author":[{"given":"Xuxu","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Yangpu District Shidong Hospital of Shanghai","place":["Yangpu District, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shepeng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yangpu District Shidong Hospital of Shanghai","place":["Yangpu District, China"]},{"name":"Department of Neurosurgery, University of Shanghai for Science and Technology","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yangpu District Shidong Hospital of Shanghai","place":["Yangpu District, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"685454","DOI":"10.3389\/fneur.2021.685454","article-title":"Outcomes and treatment complications of intravenous urokinase thrombolysis in acute ischemic stroke in China","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jama.2024.23480","article-title":"Intra-arterial urokinase after endovascular reperfusion for acute ischemic stroke: the POST-UK randomized clinical trial","volume":"333","author":"Liu","year":"2025","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jama.2024.23466","article-title":"Intra-arterial tenecteplase after reperfusion for large vessel occlusion stroke: the POST-TNK randomized clinical trial","volume":"333","author":"Huang","year":"2025","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1001\/jama.2025.16876","article-title":"Intra-arterial alteplase after successful endovascular reperfusion in acute stroke: the PEARL randomized clinical trial","volume":"334","author":"Jin","year":"2025","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jama.2025.10800","article-title":"Intra-arterial tenecteplase for acute stroke after successful endovascular therapy: the ANGEL-TNK randomized clinical trial","volume":"334","author":"Miao","year":"2025","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1209","DOI":"10.1016\/j.wneu.2022.05.143","article-title":"Urokinase is safe and effective in reducing recurrence in chronic subdural hematoma after burr-hole drainage","volume":"164","author":"Cheung","year":"2022","journal-title":"World Neurosurg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e45320","DOI":"10.7759\/cureus.45320","article-title":"Urokinase salvage therapy for recurrent chronic subdural hematoma caused by dual antiplatelet therapy","volume":"15","author":"Bao","year":"2023","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1177\/1358863X211042930","article-title":"Catheter-directed thrombolysis for deep vein thrombosis: 2021 update","volume":"26","author":"Goldhaber","year":"2021","journal-title":"Vasc Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4046\/trd.2022.0168","article-title":"Intrapleural fibrinolysis with urokinase versus alteplase in complicated pleural effusions and empyema: a prospective randomized controlled trial","volume":"87","author":"Adhikari","year":"2024","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.282.21.2003","article-title":"Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study\u2014a randomized controlled trial","volume":"282","author":"Furlan","year":"1999","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1097\/JCMA.0000000000000973","article-title":"Urokinase administration for intraventricular hemorrhage in adults: a retrospective analysis of hemorrhage volume reduction and clinical outcomes","volume":"86","author":"Li","year":"2023","journal-title":"J Chin Med Assoc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10143-025-03615-w","article-title":"Comparative efficacy of urokinase and recombinant tissue-type plasminogen activators in intraventricular hemorrhage","volume":"48","author":"Yang","year":"2025","journal-title":"Neurosurg Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1188717","DOI":"10.3389\/fneur.2023.1188717","article-title":"Minimally-invasive bedside catheter haematoma aspiration followed by local thrombolysis in spontaneous supratentorial intracerebral haemorrhage: a retrospective single-center study","volume":"14","author":"Hieber","year":"2023","journal-title":"Front Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e00293","DOI":"10.1016\/j.neurot.2023.10.003","article-title":"Minimally invasive puncture combined with a high frequency of urokinase therapy improves outcomes in patients with HICH","volume":"21","author":"Xiong","year":"2024","journal-title":"Neurotherapeutics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/j.wneu.2021.03.029","article-title":"Fibrinolytic-facilitated chronic subdural hematoma drainage\u2014a systematic review","volume":"150","author":"O","year":"2021","journal-title":"World Neurosurg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101669","DOI":"10.1016\/j.jvsv.2023.08.010","article-title":"Comparative outcomes of catheter-directed thrombolysis versus AngioJet pharmacomechanical catheter-directed thrombolysis for treatment of acute iliofemoral deep vein thrombosis","volume":"12","author":"Kang","year":"2024","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1055\/a-2106-3754","article-title":"Catheter-directed thrombolysis protocols for deep venous thrombosis of the lower extremities\u2014a systematic review and meta-analysis","volume":"124","author":"Duarte-Gamas","year":"2024","journal-title":"Thromb Haemost"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1675768","DOI":"10.3389\/fcvm.2025.1675768","article-title":"A comparative study of anticoagulation combined with different catheter-directed thrombolysis strategies (urokinase catheter-directed vs. alteplase infusion) in the treatment of intermediate-risk pulmonary embolism","volume":"12","author":"Huang","year":"2026","journal-title":"Front Cardiovasc Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.3390\/jcm12124006","article-title":"Urokinase versus alteplase in patients with intermediate\u2013high-risk pulmonary embolism treated with ultrasound-accelerated endovascular thrombolysis","volume":"12","author":"Al-Terki","year":"2023","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"219","DOI":"10.21037\/jtd-2025-aw-2267","article-title":"Efficacy and safety of urokinase in the treatment of loculated pleural effusions caused by various etiologies: a systematic review and meta-analysis","volume":"18","author":"Jiang","year":"2026","journal-title":"J Thorac Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12879-024-08975-0","article-title":"Urokinase in the treatment of tuberculous pleurisy: a systematic review and meta-analysis","volume":"24","author":"Jing","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3390\/jcm10112230","article-title":"Locked away\u2014prophylaxis and management of catheter-related thrombosis in hemodialysis","volume":"10","author":"Szyma\u0144ska","year":"2021","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0251793","DOI":"10.1371\/journal.pone.0251793","article-title":"Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: a randomized double-blind trial","volume":"16","author":"Bonkain","year":"2021","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/1129729820950997","article-title":"Prospective audit to study urokinase use to restore patency in occluded centRal venous caTheters in haematology and oncology patients (PASSPORT 2)","volume":"22","author":"Kumwenda","year":"2021","journal-title":"J Vasc Access"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1161\/STR.0000000000000456","article-title":"Diagnosis and management of cerebral venous thrombosis: a scientific statement from the American Heart Association","volume":"55","author":"Saposnik","year":"2024","journal-title":"Stroke"},{"key":"B26","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/jamaneurol.2020.1022","article-title":"Effect of endovascular treatment with medical management vs. standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial","volume":"77","author":"Coutinho","year":"2020","journal-title":"JAMA Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1519308","DOI":"10.3389\/fneur.2025.1519308","article-title":"Sliding balloon-assisted thrombectomy combined with aspiration and intrasinus urokinase thrombolysis for the treatment of hemorrhagic cerebral venous sinus thrombosis: experience of 10 patients","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2325415","DOI":"10.1001\/jamanetworkopen.2023.25415","article-title":"Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5\u2005h of stroke onset: a phase 3 randomized clinical trial","volume":"6","author":"Song","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1474-4422(24)00436-8","article-title":"Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4\u00b75\u2005h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial","volume":"24","author":"Li","year":"2025","journal-title":"Lancet Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/brainsci15050466","article-title":"Efficacy and safety of recombinant human prourokinase in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Sabet","year":"2025","journal-title":"Brain Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamaneurol.2024.4688","article-title":"Prourokinase vs. standard care for patients with mild ischemic stroke: the PUMICE randomized clinical trial","volume":"82","author":"Xiong","year":"2025","journal-title":"JAMA Neurol"}],"updated-by":[{"DOI":"10.3389\/fcvm.2026.2017216","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000}}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1904249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:21:54Z","timestamp":1792664514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1904249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":31,"alternative-id":["10.3389\/fcvm.2026.1904249"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1904249","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1904249"}}